MedTrace Logo

A Proof-of-Concept Study to Evaluate the Efficacy of NOBO, a Novel Postbiotic, in Controlling Axillary Odor in Healthy Adults

NCT07547761 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-05-11

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the performance of NOBO, a yeast-based fermentation product (postbiotic) designed to control axillary odor, in controlling axillary odor in healthy male and female adults age 18 - 70 with confirmed self-perception of body odor. The main question it aims to answer is:

Does NOBO decrease self-perceived odor of the intervention axilla compared to the placebo axilla at any time point? Researchers will compare the intervention axilla to the placebo axilla to see if there is a difference in self-perceived odor and microbiome.

Participants will:

* be given a NOBO deodorant spray and a placebo deodorant spray (each assigned to one axilla)
* self assess body odor
* sample axilla with cotton round for 3rd party odor assessment
* sample axilla with a swab for skin microbiome analysis via qPCR
* self assess skin irritation

Conditions

  • Body Odor

Interventions

OTHER

NOBO Aqueous Deodorant

The active ingredient in the NOBO aqueous deodorant is a yeast-based fermentation product (postbiotic) of the Starmerella genus.

OTHER

Placebo Aqueous Deodorant

The placebo deodorant is composed of ≤ 40% ethanol in water.

Sponsors & Collaborators

  • Kingdom

    lead INDUSTRY

Principal Investigators

  • Aylesse Sordillo, PhD · Principal Scientist at Kingdom

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-16
Primary Completion
2026-05-04
Completion
2026-05-04

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07547761 on ClinicalTrials.gov